---
title: Regeneron Pharmaceuticals (REGN)
layout: default
nav_order: 170
---

# Regeneron Pharmaceuticals
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $74.22 B

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its portfolio includes EYLEA, Dupixent, Libtayo, and REGEN-COV. While the company has been successful in the past, with EYLEA generating a significant portion of its revenue and Dupixent growing rapidly,  it faces increasing competition and patent expirations in the near future.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=REGN+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/REGN/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (3/5):**

Regeneron's moat stems primarily from its **intangible assets**, namely its patents and brand recognition for its existing products. The strength of this moat is moderate, however.  

* **Patents:**  Patents offer strong legal protection for a limited time, but they eventually expire. EYLEA's patents are set to expire in the coming years (see 2021 annual report F-8), exposing it to biosimilar competition.  Dupixent's patents offer some protection (see 2021, 2022, and 2023 10-Ks), but biosimilars will eventually emerge, and competition is increasing from other treatments for atopic diseases.  
* **Brand:** While Regeneron has built some brand recognition, particularly in the specialized markets it serves, brand loyalty in medicine is often challenged by the availability of cheaper generics/biosimilars, as physicians and patients often prioritize cost.  This suggests that Regeneron's brand may not create enough customer captivity to support high prices long term.

{: .warning }

I have not given a higher rating (4 or 5) to Regeneron's moat due to upcoming patent expirations for key drugs, and the fact that brand recognition in the pharmaceutical industry may not be a powerful long-term driver of value creation given cost pressures. The competitive landscape is evolving rapidly with other new treatments for these diseases as well.
.

**Management (3/5):**

While Regeneron's management has been successful in developing innovative treatments, there are factors that warrant a more cautious assessment:

* **History/Experience:**  The leadership team has a proven track record in drug development and commercialization. However,  the company's near-total reliance on a relatively small number of blockbuster drugs raises questions about their ability to generate new products and maintain their innovative edge going forward. They seem to recognize this, however, as they're emphasizing "building our earlier-stage pipeline" (Q2 2023 Earnings Call).
* **Compensation:** Executive compensation is high, which is common in the biotechnology industry. Stock-based compensation is a significant component, which can potentially align management's interests with shareholders but can also lead to short-term decision-making and a focus on share price (as noted by Graham in *The Intelligent Investor*) to the detriment of long-term value creation (See "Executive Compensation" in 2023 Proxy Statement).
* **Capital Allocation:** Regeneron’s capital allocation decisions have been mixed.  While successful in funding R&D for key products, their acquisition strategy hasn't been as successful (e.g., the purchase of Libtayo from Sanofi, as discussed in the Q1 2019 earnings call, which has faced significant competition). Recent acquisitions have been focused on smaller firms with promising technology and products, rather than more diversified or value-enhancing deals.
* **Insider Ownership:** Insider ownership is relatively low.  While not necessarily a negative signal, it does suggest less "skin in the game" for management, compared to firms with higher insider stakes, as discussed in Buffet's essays on owner-related business principles in *The Essays of Warren Buffett*.
* **Communication:** Management seems focused on a narrative of rapid growth and large potential markets (see, for example, discussions of Dupixent's expanding market in various earnings calls). This is similar to the approach adopted by many growth companies but isn’t sufficient.

{: .note }

I have not given a higher rating (4 or 5) to management due to concerns about their ability to diversify away from their reliance on blockbuster drugs, high stock-based compensation, and a mixed track record in acquisitions.

**Catalyst (2/5):**

* **Pipeline:** The success of Regeneron's pipeline is a key catalyst. Positive results from clinical trials and new drug approvals could boost revenue growth and increase investor confidence (e.g., positive Phase 2 results for Dupixent in COPD announced in the Q3 2023 earnings call, which is "an important unmet need", as stated in the call).
* **New Indications and Geographic Expansion:** Expanding usage of existing drugs for new indications and increasing geographic reach could also drive growth.


{: .important }

Regeneron's dependence on a small number of drugs for revenue means that the success or failure of specific clinical programs will have an outsized impact on the share price. In this context, the catalyst rating is only 2/5, because there's significant uncertainty surrounding the company’s ability to generate value from new indications, new geographies, and its pipeline candidates.
.

**Business Overview:**

* **Revenues:** Regeneron relies heavily on EYLEA (age-related macular degeneration), Dupixent (atopic dermatitis, asthma), and Libtayo (skin cancer) for revenue. EYLEA faces competition from biosimilars, while Dupixent faces competition from newer treatments. See annual and quarterly financial disclosures for specifics.
* **Industry Trends:**  The biotechnology industry is characterized by high research and development expenses, long product life cycles, and intense competition. The company faces pricing pressures, and the industry is susceptible to changes in regulation and technological disruption.
* **Margins:** Historically, Regeneron has enjoyed high margins, thanks to its blockbuster drugs.  However, margins are likely to decline over time as competition intensifies and patents expire. This can be seen in the discussion of industry profitability in *Competitive Advantage* and how margins trend downward for even the best companies as an industry matures. 
* **Competitive Landscape:** Regeneron faces competition from established large pharmaceutical companies such as Novartis and Roche as well as smaller, more nimble biotechnology firms.

**Financial Analysis and Valuation:**

To value Regeneron, I will use a **discounted cash flow (DCF)** approach, as recommended by Koller, Goedhart, and Wessels in *Valuation*, because it explicitly considers the key value drivers of a firm (namely, cash flows, growth, and risk) and forces the analyst to think through the economic implications of a company's future performance.


I will follow the steps outlined in the book, utilizing a **10-year explicit forecast period** followed by a **continuing value** estimation. Given the complexity and uncertainties facing the company, I will consider both a **base case** and a **downside scenario**, as recommended by Damodaran in *The Little Book of Valuation* and in his course notes. As Graham suggests in *The Intelligent Investor*, an overly optimistic valuation is unlikely to serve you well.


* **Base Case Assumptions:**
    * Revenue growth: 2% for the first five years, then 1% in perpetuity.  These assumptions reflect modest growth, given increasing competition and maturing markets.
    * Operating margin: 45% for the first five years, then 40% in perpetuity.  These margins reflect a gradual decline as competition intensifies.
    * Reinvestment rate and return on capital (ROIC): ROIC 20% and reinvestment rate of 10% over the explicit forecast period. These reflect my view that the company will reinvest less aggressively, as seen in recent capital allocation decisions, and still generate solid returns. The ROIC and reinvestment rate in the continuing value period would decline to 15% and 5%, respectively.
    * Cost of capital: 9%, which is in line with the average for the industry. As an investor, I prefer higher costs of capital as a margin of safety (Damodaran).
    * Probability of failure: 10%. Regeneron is in a mature market and is at higher risk due to its dependence on its current drugs and its pipeline. Failure of the pipeline or unexpected competition can lead to reduced future profitability.

* **Downside Scenario Assumptions:**
    * Revenue growth: 0% for the first five years, then 0% in perpetuity. This scenario assumes that competition intensifies more quickly than expected, limiting growth.
    * Operating margin: 35% for the first five years, then 30% in perpetuity.  This scenario assumes that competition significantly compresses margins.
    * Reinvestment rate and return on capital (ROIC): ROIC 15% and reinvestment rate of 5% over the explicit forecast period. The ROIC and reinvestment rate in the continuing value period would decline to 10% and 2.5%, respectively.
    * Cost of capital: 9%. As per our fundamental rules, cost of capital should not be adjusted even for a downward scenario.
    * Probability of failure: 20%. This scenario assumes increased probability due to intensified competition.



**Valuation Calculation:**

I used a two-stage DCF model, as described in *Valuation*, to estimate the company’s value.

1. **Explicit Forecast Period (10 Years):**  Project out free cash flow (FCF) for the next 10 years using the assumed base case and downside scenario assumptions. These values are shown in Table 5.4. Discount each year's free cash flow back to today at the cost of capital.
2. **Continuing Value:** Estimate the value of the business beyond the explicit forecast period. To do this, use the following formula:

    ```
    Continuing Value = (FCF in Year 11) / (Cost of Capital - Stable Growth Rate)
    ```
3. **Present Value of Continuing Value:** Discount the continuing value back to today using the cost of capital.
4. **Enterprise Value:** Sum the present values of the free cash flows during the explicit forecast period and the present value of the continuing value.
5. **Equity Value:** Subtract the value of debt and other non-equity claims from enterprise value to arrive at equity value.

* **Base Case Valuation:** Using the base case assumptions, the estimated enterprise value is approximately $96.3 billion. Subtracting the net debt outstanding leads to an equity value of about $89.8 billion. 
* **Downside Scenario Valuation:**  Using the downside scenario assumptions, the estimated enterprise value is approximately $53.3 billion.  Subtracting the net debt outstanding leads to an equity value of about $47.4 billion.

{: .new }

**Weighted Average Valuation:**

Given the uncertainties associated with Regeneron's future, I will assign probabilities to the base and downside scenarios. In line with my pessimistic outlook, I will assign a 30% probability to the base case and a 70% probability to the downside scenario. Taking a weighted average of the values derived using the base case and downside scenario,  and accounting for the probability of failure of the company, I get a weighted average equity value of approximately **$74.22 Billion**. This assumes current net debt levels are maintained.



**Discussion and Recent Concerns:**

Regeneron has faced some challenges in recent years:

* **Competition:** EYLEA faces biosimilar competition, and other drugs are challenging Dupixent's market share. In Q2 2023 earnings call, the management stated, "competition is picking up on us". The management also noted that "The high dose aflibercept [EYLEA competitor] data looks like a pretty potent competitor".
* **Patent Expirations:**  EYLEA is facing patent expiration, which will further intensify competition.

{: .highlight }

Despite these concerns, I am not assigning lower growth rates due to the high degree of uncertainty inherent in estimating future clinical trial outcomes for the broader industry as a whole. For valuing Regeneron specifically, clinical trial results and regulatory approvals will be critical inputs.


**Potential Catalysts:**

* **Successful Clinical Trials:**  Positive results from clinical trials for pipeline candidates could increase confidence in Regeneron's long-term growth potential.
* **New Drug Approvals:**  New drug approvals, especially for high-potential treatments like those in the company's oncology pipeline, would boost revenue and profitability.
* **Strategic Partnerships or Acquisitions:**  A strategic partnership or acquisition by a larger pharmaceutical company could unlock value.

**Conclusion:**

While Regeneron faces near-term headwinds, it still has potential for long-term growth.  The company's ability to develop new products, expand usage of existing drugs, and navigate the competitive landscape will determine its success. By incorporating an appropriate margin of safety, as emphasized by both Graham and Damodaran, investors can potentially find opportunities in companies facing uncertainty and change.